In a report released on September 16, Stephanie Davis from SVB Securities maintained a Buy rating on Health Catalyst (HCAT – Research Report), with a price target of $20.00. The company’s shares closed last Friday at $10.32.
According to TipRanks, Davis is an analyst with an average return of -2.7% and a 46.43% success rate. Davis covers the Technology sector, focusing on stocks such as NextGen Healthcare, Allscripts, and Tabula Rasa HealthCare.
In addition to SVB Securities, Health Catalyst also received a Buy from J.P. Morgan’s Anne Samuel in a report issued on September 4. However, on September 13, Piper Sandler downgraded Health Catalyst (NASDAQ: HCAT) to a Hold.
HCAT market cap is currently $564.7M and has a P/E ratio of -3.54.
Based on the recent corporate insider activity of 97 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HCAT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.
Read More on HCAT: